文献速递核素与放射性配体治疗

神经内分泌肿瘤的靶向α发射体治疗

Targeted α-Emitter Therapy of Neuroendocrine Tumors.
PubMed 文献 · Semin Nucl Med · 2020-01-01

神经内分泌肿瘤(NET)发病率与检出率近年显著上升;肽受体放射性核素治疗(PRRT)使用生长抑素类似物高效且耐受良好,可改善生存参数。当前PRRT使用β发射体,但肿瘤缺氧可致耐药,且穿透程较长带来副作用;α粒子能量更高、穿透程更短,在靶向治疗中具优势。基于生长抑素的靶向α治疗(TAT)在NET中显示很有希望的结果,甚至对β发射体难治患者亦如此;本文总结NET中TAT的临床前与临床研究进展。

要点

  • NET发病率与检出率近年显著上升,PRRT使用生长抑素类似物高效且耐受良好。
  • 当前PRRT使用β发射体,肿瘤缺氧可致耐药,穿透程较长带来副作用。
  • α粒子能量更高、穿透程更短,基于生长抑素的TAT在NET中显示很有希望的结果。

核心结论

  • 基于生长抑素的靶向α治疗在NET中显示很有希望的结果,甚至对β发射体难治患者亦如此。

研究设计与样本

  • 本文为综述,总结NET中靶向α治疗(TAT)的临床前与临床研究进展。

主要发现

  • NET发病率与检出率近年显著上升;PRRT使用生长抑素类似物高效且耐受良好,可改善生存参数。
  • 当前PRRT使用β发射体,肿瘤缺氧可致耐药,穿透程较长带来副作用。
  • α粒子能量更高、穿透程更短,在靶向治疗中具优势;基于生长抑素的TAT在NET中显示很有希望的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, arising from cells of the endocrine system, with various clinical behaviors. Although these neoplasms are considered rare, a significant increase in the incidence and detectability of NET has been noted in many epidemiological studies in recent years. Among the various therapeutic options, peptide receptor radionuclide therapy (PRRT), using somatostatine has been shown to be highly effective and a well-tolerated therapy, improving survival parameters. The current use of radionuclides for PRRT is β-emitters. Due to hypoxia cancer tissue could be resistant for β-emitters. Quite long penetration range had a significant impact on side effects. α-particles with higher energy and shorter penetration range in comparison to β-particles, have distinct advantages for use in targeted therapy. The clinical experience with somatostatine based targeted α therapy (TAT) in NET showed very promising results even in patienicts refractory to treatment with β-emitters. This article summarizes current developments in preclinical and clinical investigation on TAT in NET.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kunikowska J, Królicki L. Targeted α-Emitter Therapy of Neuroendocrine Tumors. Semin Nucl Med. 2020. PMID: 32172802. doi:10.1053/j.semnuclmed.2019.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。